Interleukin-1 blockade in cardiac sarcoidosis: study design of the multimodality assessment of granulomas in cardiac sarcoidosis: Anakinra Randomized Trial (MAGiC-ART).
Cardiac sarcoidosis
Heart failure
Inflammation
Interleukin-1
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
08 11 2021
08 11 2021
Historique:
received:
01
09
2021
accepted:
23
10
2021
entrez:
9
11
2021
pubmed:
10
11
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Sarcoidosis is an inflammatory disease characterized by the formation of granulomas, which involve the heart in up to 25% of patients. Cardiac sarcoidosis can lead to life threatening arrhythmias and heart failure. While corticosteroids have been used as a treatment for over 50 years, they are associated with hypertension, diabetes, and weight gain, further increasing cardiovascular risk. Interleukin-1 (IL-1) is the prototypical proinflammatory cytokine that works to activate the nuclear transcription factor NF-kB, one of the targets of glucocorticoids. IL-1 also plays an important role also in the pathophysiology of heart disease including atherosclerosis, myocardial infarction, and myocarditis. Building on a network of research collaborators developed in the Cardiac Sarcoidosis Consortium, we will investigate the feasibility and tolerability of treatment of CS with anakinra at two National Institute of Health Clinical and Translational Science Award (CTSA) hubs with expertise in cardiac sarcoidosis. In this pilot study, up to 28 patients with cardiac sarcoidosis will be recruited to compare the administration of an IL-1 blocker, anakinra, 100 mg daily on top of standard of care versus standard of care only for 28 days and followed for 180 days. Utilizing surrogate endpoints of changes in systemic inflammatory biomarkers and cardiac imaging, we aim to determine whether IL-1 blockade with anakinra can combat systemic and cardiac inflammation in patients with cardiac sarcoidosis. The current trial demonstrates an innovative collaborative approach to clinical trial development in a rare, understudied disease that disproportionately affects females and minorities. Trial Registration The trial was registered prospectively with ClinicalTrials.gov on July 12, 2019, identifier NCT04017936.
Sections du résumé
BACKGROUND
Sarcoidosis is an inflammatory disease characterized by the formation of granulomas, which involve the heart in up to 25% of patients. Cardiac sarcoidosis can lead to life threatening arrhythmias and heart failure. While corticosteroids have been used as a treatment for over 50 years, they are associated with hypertension, diabetes, and weight gain, further increasing cardiovascular risk. Interleukin-1 (IL-1) is the prototypical proinflammatory cytokine that works to activate the nuclear transcription factor NF-kB, one of the targets of glucocorticoids. IL-1 also plays an important role also in the pathophysiology of heart disease including atherosclerosis, myocardial infarction, and myocarditis.
METHODS
Building on a network of research collaborators developed in the Cardiac Sarcoidosis Consortium, we will investigate the feasibility and tolerability of treatment of CS with anakinra at two National Institute of Health Clinical and Translational Science Award (CTSA) hubs with expertise in cardiac sarcoidosis. In this pilot study, up to 28 patients with cardiac sarcoidosis will be recruited to compare the administration of an IL-1 blocker, anakinra, 100 mg daily on top of standard of care versus standard of care only for 28 days and followed for 180 days. Utilizing surrogate endpoints of changes in systemic inflammatory biomarkers and cardiac imaging, we aim to determine whether IL-1 blockade with anakinra can combat systemic and cardiac inflammation in patients with cardiac sarcoidosis.
DISCUSSION
The current trial demonstrates an innovative collaborative approach to clinical trial development in a rare, understudied disease that disproportionately affects females and minorities. Trial Registration The trial was registered prospectively with ClinicalTrials.gov on July 12, 2019, identifier NCT04017936.
Identifiants
pubmed: 34749739
doi: 10.1186/s12967-021-03130-8
pii: 10.1186/s12967-021-03130-8
pmc: PMC8575149
doi:
Substances chimiques
Interleukin 1 Receptor Antagonist Protein
0
Interleukin-1
0
Banques de données
ClinicalTrials.gov
['NCT04017936']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
460Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR002649
Pays : United States
Organisme : Pauley Heart Center
ID : Pilot Grant
Organisme : NCATS NIH HHS
ID : TR003103-01
Pays : United States
Organisme : American Heart Association
ID : 19CSL0134580004
Informations de copyright
© 2021. The Author(s).
Références
Lancet. 2018 Jan 27;391(10118):319-328
pubmed: 29146124
JACC Cardiovasc Imaging. 2017 Apr;10(4):411-420
pubmed: 27450877
J Nucl Med. 2014 Jan;55(1):99-106
pubmed: 24232870
Respiration. 2000;67(4):389-96
pubmed: 10940792
Sarcoidosis. 1988 Sep;5(2):142-46
pubmed: 3227188
JAMA. 2006 May 17;295(19):2275-85
pubmed: 16705109
Cochrane Database Syst Rev. 2005 Apr 18;(2):CD001114
pubmed: 15846612
Minerva Med. 2021 Jul 16;:
pubmed: 34269550
Eur J Heart Fail. 2019 Mar;21(3):385-386
pubmed: 30666820
J Clin Transl Sci. 2021 Apr 08;5(1):e136
pubmed: 34367680
PLoS One. 2012;7(3):e33438
pubmed: 22438931
Lancet. 2014 Mar 29;383(9923):1155-67
pubmed: 24090799
Circulation. 2009 Nov 17;120(20):1969-77
pubmed: 19884472
Am J Epidemiol. 1997 Feb 1;145(3):234-41
pubmed: 9012596
J Card Fail. 2021 Jan;27(1):83-91
pubmed: 32889044
J Am Coll Cardiol. 2005 May 17;45(10):1683-90
pubmed: 15893188
Circulation. 2019 Mar 5;139(10):1289-1299
pubmed: 30586730
Rheumatology (Oxford). 2018 Oct 1;57(57 Suppl 7):vii5-vii10
pubmed: 30289535
Am J Respir Crit Care Med. 1995 Mar;151(3 Pt 1):920-1
pubmed: 7881695
Antioxid Redox Signal. 2015 May 1;22(13):1146-61
pubmed: 25330141
Nat Rev Cardiol. 2018 Apr;15(4):203-214
pubmed: 29143812
Circ Arrhythm Electrophysiol. 2019 Sep;12(9):e007582
pubmed: 31522533
Circ Heart Fail. 2017 Nov;10(11):
pubmed: 29141858
J Am Heart Assoc. 2020 Jun 2;9(11):e015594
pubmed: 32427023
Eur Heart J. 2018 Jun 7;39(22):2063-2069
pubmed: 29584915
Chest. 2011 Jan;139(1):144-50
pubmed: 20595459
N Engl J Med. 2017 Sep 21;377(12):1119-1131
pubmed: 28845751
Am J Cardiol. 2015 Feb 1;115(3):288-92
pubmed: 25482680
Heart Rhythm. 2014 Jul;11(7):1305-23
pubmed: 24819193
Circulation. 2003 Jul 1;107(25):3133-40
pubmed: 12796126
Circ Cardiovasc Imaging. 2012 Jan;5(1):102-10
pubmed: 22038988
Blood. 2011 Apr 7;117(14):3720-32
pubmed: 21304099
Radiographics. 2009 Jan-Feb;29(1):89-103
pubmed: 19168838
Am J Respir Crit Care Med. 2015 Apr 1;191(7):786-95
pubmed: 25594886
J Am Coll Cardiol. 2017 Oct 31;70(18):2278-2289
pubmed: 29073957
N Engl J Med. 2019 Feb 21;380(8):752-762
pubmed: 30415610
Eur Respir J. 2006 Sep;28(3):627-36
pubmed: 16946094
Am J Cardiol. 2014 Jan 15;113(2):321-327
pubmed: 24262762
Am J Pathol. 1988 Mar;130(3):629-38
pubmed: 3258127
J Am Coll Cardiol. 2014 Feb 4;63(4):329-36
pubmed: 24140661